Clinical Trials Search at Vanderbilt-Ingram Cancer Center

This phase IV trial assesses the safety and feasibility of receiving chimeric antigen receptor (CAR) T cell therapy with YESCARTA in the outpatient setting, with fewer days spent as a patient in the hospital. YESCARTA is made from your own white blood cells, which will be modified in a laboratory to recognize and attack your lymphoma cells. Because YESCARTA is a specialized and fairly new therapy, patients currently receiving YESCARTA are typically required to spend several days in the hospital even if their treatment is well tolerated. This trial may help doctors determine if it is safe and feasible to give YESCARTA in the outpatient setting, with fewer days spent as a patient in the hospital.